PiUS
|
- $282 - $555
- Product name: PiUS
- CAS:
- MF:
- MW: 0
- EINECS:
- MDL Number:
- Synonyms:Anti-IP6K1 antibody produced in rabbit;PiUS;IHPK1;Inositol hexakisphosphate kinase 2;IP6K2;InsP6 kinase 2;P(i)-uptake stimulator;Anti-Inositol hexakisphosphate kinase 1
3 prices
Selected condition:
Brand
- Sigma-Aldrich
Package
- 25μL
- 100μL
- ManufacturerSigma-Aldrich
- Product numberHPA040825
- Product descriptionAnti-IP6K1 antibody produced in rabbit Prestige Antibodies? Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
- Packaging25μL
- Price$282
- Updated2023-06-20
- Buy
- ManufacturerSigma-Aldrich
- Product numberSAB2701994
- Product descriptionAnti-IP6K1 antibody produced in rabbit
- Packaging100μL
- Price$512
- Updated2025-07-31
- Buy
- ManufacturerSigma-Aldrich
- Product numberHPA040825
- Product descriptionAnti-IP6K1 antibody produced in rabbit Prestige Antibodies? Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
- Packaging100μL
- Price$555
- Updated2025-07-31
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Sigma-Aldrich | HPA040825 | Anti-IP6K1 antibody produced in rabbit Prestige Antibodies? Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution | 25μL | $282 | 2023-06-20 | Buy |
Sigma-Aldrich | SAB2701994 | Anti-IP6K1 antibody produced in rabbit | 100μL | $512 | 2025-07-31 | Buy |
Sigma-Aldrich | HPA040825 | Anti-IP6K1 antibody produced in rabbit Prestige Antibodies? Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution | 100μL | $555 | 2025-07-31 | Buy |
Properties
storage temp. :-20°C
form :liquid
biological source :rabbit
form :liquid
biological source :rabbit
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||
Precautionary statements: |
|